Latest From Ergomed PLC
Appointments: IFPMA, German Merck, Ergomed, Spectrum, Astellas, Laboratoris Sanifit and Audentes Therapeutics
Appointment announcements this week include Greg Perry becoming the IFPMA’s new assistant director general, a new head of corporate affairs at German Merck, new CEOs at Ergomed and Spectrum, and other senior hires at Astella Americas, Laboratoris Sanifit, and a new board member at Audentes Therapeutics Inc.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The biggest Phase III trial in head and neck cancer is resuming after the FDA lifted a freeze on trials evaluating CEL-SCI's lead asset Multikine in the indication, giving a boost to its commercial prospects.
This week's roundup includes CEO appointments by Tiziana and Ergomed and executive appointments by Crescendo Biologics, Ablynx, Alexion and Axcella. In addition to this, Oxford BioTherapeutics and Kymab have announced board appointments.
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- Ergomed PLC
- Senior Management
Miroslav Reljanovic , MD, CEO
Stephen Stamp, CFO
Andrew Mackie, CBO
- Contact Info
Phone: 1483 503 205
26 Frederick Sanger Rd.
Surrey , GU2 7YD
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.